Sinocelltech launches IPO on STAR Market

On 22 June, Sinocelltech Group Limited (" Sinocelltech") made its initial public offering ("IPO") on the SSE STAR Market (stock code: 688520). Sinocelltech applied the fifth set of listing standards on the Sci-Tech Innovation Board. The issuance raised a total of RMB 1.282 billion by issuing 50 million new shares at the price of RMB 25.64 each.

Sinocelltech is an innovative biopharmaceutical R&D and industrial development company dedicated to the development of biomedicines with differentiated competitive advantages. It focuses on multiple therapeutic and preventive fields such as malignant tumors, autoimmune diseases, infectious diseases and genetic diseases.

As the issuer's counsel, King & Wood Mallesons (KWM) provided legal services in relation to the demonstration of listing path scheme, employee equity incentive, etc. throughout the listing process to successfully land on the Sci-Tech innovation board.

The KWM team included partners Gao Yimin and Jia Diyan, with support from senior associate Liu Zhihui. Jiang Yifeng is the lead partner.